Sol-Gel Technologies Ltd. Board of Directors

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Dr. Alon Seri-Levy

Dr. Alon Seri-Levy

Co-Founder, CEO & Director

Dr. Itzik Yosef

Dr. Itzik Yosef

Chief Operating Officer

Mr. Moshe Arkin

Mr. Moshe Arkin

Executive Chairman of the Board

Mr. Eyal Ben-Or

Mr. Eyal Ben-Or

Chief Financial Officer

Dr. Karine Neimann

Dr. Karine Neimann

VP of Projects & Planning and Chief Chemist

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.